The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1690
November 27, 2023
View Complete Issue         Table of Contents 2019 
Ritlecitinib (Litfulo) for Severe Alopecia Areata
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ritlecitinib (Litfulo) for Severe Alopecia Areata
November 27, 2023 (Issue: 1690)
The FDA has approved ritlecitinib (Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ritlecitinib (Litfulo) for Severe Alopecia Areata
Article code: 1690a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.